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Abstract
The aim of our study was to investigate insulin sensitivity
and beta cell function in hemodialysis (HD) patients without
diabetes.  We hypothesized that parathyroid gland function was
a determinant of insulin sensitivity and/or beta cell function.
The study was a randomized, cross-sectional one and patients
were divided into two groups (total 27 patients), Gp.1 being those
with relative hypoparathyroidism (iPTH<200 pg/ml) –
9 (33.3%), Gp.2 those with hyperparathyroidism
(iPTH≥200 pg/ml) – 18 (66.6%) with Gp.3 (consisting of 43
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healthy subjects acting as controls).  Insulin resistance and
insulin secretion were calculated from fasting serum insulin and
glucose concentrations by the Homeostatic Model Assessment
score (HOMA IR and HOMA BETA).  The value of HOMA IR
(3.28±1.3 for Gp.1, 4.80±2.4 for Gp.2, 1.70±0.8 for Gp.3) as
well as the glucose level (5.0±1.0mmol/l in Gp.1, 5.2±0.8mmol/
l in Gp.2, 4.6±0.4mmol/l in Gp.3) was significantly higher in
HD patients than in control subjects.  Excessive insulin secretion
was present in HD patients (as assessed by HOMA BETA)
significantly higher only in Gp.1 (p=0.02).  HOMA IR was higher
in Gp.2 than in Gp.1 (p=0.05), and both groups had higher levels
of HOMA IR than the control group (Gp.1/Gp.1 p=0.03; Gp.2/
Gp.3 p=0.00).  A positive correlation between HOMA IR and
serum iPTH was seen in Gp.2 only (r=0.54, p=0.03).  HOMA
BETA inversely correlated with Ca x iP product in Gp.1 (r=0.54,
p=0.04).  The only significant negative correlation between
HOMA BETA and age (r= -0.59, p=0.01) was registered in Gp.2.
Serum iPTH correlated positively with serum Ca2+ (r= 0.49,
p=0.03) in Gp.2.
In conclusion, our study demonstrated the presence of a
higher level of serum insulin and insulin resistance in HD
patients.  Serum iPTH directly correlated with the insulin
resistance index in hyperparathyroid patients suggesting a
possible interaction between PTH and the insulin signaling
pathway.  Excessive insulin secretion was registered in HD
patients, significantly higher only in hypoparathyroid patients.
However, beta cells function in both groups of patients was
preserved implying relatively good sensitivity of the calcium
receptor (CaR) in beta cells.
Introduction
A number of studies in uremic patients reported that insulin
resistance, reduced beta cell secretion and glucose intolerance
leading to dyslipidemia are associated with hyper-
parathyroidism.1-3  It was observed that hyperprathyroidism-
induced increase in cytosolic calcium could be responsible for
beta-cell dysfunction.  These alterations were reversed with
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verapamil and recurred after discontinuation of the drug.1
Changes in intracellular calcium concentration have a central
role in various cellular processes, from growth and development
to hormone secretion.  Increases in intracellular ionized calcium
(Ca2+) are likely to be sustained by Ca2+ influx through voltage-
dependent Ca2+ channels (VDCC) or non-selective cation
channels (NSCC), depending on the cell type.4,5  Raised free
cytoplasmic Ca2+ levels trigger insulin secretion.  Squires et al
reported that increasing extracellular Ca2+ from 1.3 to 5mM
increases insulin secretion from human pancreatic islets in in
vitro.6  But, later, in perfusion experiments, that transient
increase in insulin secretion was followed by a Ca2+
concentration-dependent and prolonged inhibition of
secretion7.  That inhibition was fully reversible with a reduced
level of extracellular Ca2+.  This study demonstrated another,
calcium sensing receptor (CaR)-mediated inhibitory
mechanism, which may be an important auto-regulatory
mechanism in the control of insulin secretion.  A novel, small
G-protein, Kir/GEM, interacting with the beta3 isoform of the
VDCC, inhibits alpha ionic activity and prevents cell-surface
expression of alpha subunits VDCC, and could attenuate
glucose-stimulated Ca2+ increases and insulin secretion in
insulin-secreting cells.8
Elevated levels of parathyroid hormone (PTH) occur early
in renal failure.  The onset of secondary hyperparathyroidism
is the result of altered mineral and hormone metabolism,
especially a diminished synthesis of active vitamin D (calcitriol)
metabolite from the failing kidney and resistance of target tissue
toward them.  A rightward shift of the calcium set-point and an
increase of the minimum secretion rate of PTH have been found
in secondary hyperparathyroidism, indicating abnormal calcium
sensing by parathyroid cells.  It is considered that various
candidate genes, vitamin D receptor (VDR) gene, CaR gene and
PTH gene polymorphisms might contribute to progression of
secondary hyperparathyroidism9-11.  It is well known that
extracellular Ca2+  influx through L-type VDCC raises free
cytoplasmic Ca2+ level in beta cells and triggers insulin secretion.
The complications associated with chronic secondary
hyperparathyroidism are numerous and include “classic effects”
of PTH excess on kidney, bone, cardiovascular and erythropoetic
system, as well as effects on other “non-classic” targets eg
pancreas, adrenal cortex, testis and pituitary gland.
Independently of its ability to prevent secondary
hyperparathyroidism, or later to decrease elevated PTH level
and normalise serum calcium and phosphate, calcitriol is
probably a modulator of insulin secretion and insulin
sensitivity.12,13  The treatment of secondary hyperparathyroidism
with calcimimetics, new agents which potentiate the effects of
extracellular Ca2+ on the CaR, besides reducing PTH synthesis
and secretion, could make possible the identification of
secondary effects of Ca 2+ on tissues not involved in Ca2+
homeostasis, such as pancreatic islets.14
Subjects and Methods
Patient population
The total number of subjects involved in the study was 70.
Twenty seven of them were stable, end-stage renal patients (17
males and 10 females), on a chronic HD program, 4 hours three
times weekly, with HD duration more than six months.  All of
them were treated in the Hemodialysis Unit of Zemun Clinical
Hospital.  Exclusion criteria included a history of diabetes
mellitus, malignancy and cardiac and vascular failure.  The
causes of end-stage renal disease were glomerular disease,
chronic pyelonephritis, polycystic renal disease, urolithiasis and
hypoplastic kidney in 11, 7, 4, 4 and one patient, respectively.
None of them had undergone total or subtotal
parathyroidectomy or received pulsed intravenous high-dose
active vitamin D treatment.  The control group consisted of 43
healthy individuals (23 males and 20 females) without renal
failure, diabetes or any serious cardiorespiratory disease.
Study design
The study was a randomized cross-sectional one.  Each
patient was treated with dialyzers containing membranes of
cuprofan and polysulfone, and bicarbonate dialysates with a
calcium concentration of 1.75mmol/l.  Patients received calcium
carbonate as phosphate binders.  Oral active vitamin D (1,25-
dihydroxyvitamin D3) was administered to patients at dosages
0.25 to 0.5 mg/d, if hyperphosphatemia was less than 1.8 mmol/
L.  With higher serum inorganic phosphate (iP) concentration,
phosphate binder therapy was only intensified.  Serum intact
parathyroid hormone level (iPTH) measurement revealed
relative hypoparathyroidism (iPTH <200 pg/ml) in 9 (33.3%)
(Gp.1), hyperparathyroidism (iPTH≥200 pg/ml) in 18
(66.6%)(Gp.2) of 27 subjects, with mean ages of 53.7±8.3 and
49.5±7.0 years respectively.  The level of iPTH in controls could
not be estimated due to lack of sufficient funding.  The HD
duration did not differ between the two patient groups (67±15
months in Gp.1 and 79±38 months in Gp.2).  The mean age of
the control (Gp.3) was 50.3±9.6 years.
Methods
Blood samples were obtained during midweek, after 12
hours fasting and immediately prior to dialysis, for
measurement of the following variables: serum glucose, insulin,
C-peptide, iPTH, total serum proteins, albumin, BUN,
creatinine, serum ionized Ca (Ca 2+) and inorganic phosphate
(iP), which were measured by standard laboratory methods.
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Intact PTH was assessed using an immunoradiometric method
(CIS-Bio) and insulin and C-peptide were measured using a
radioimmunoassay method (INEP Zemun, Belgrade).  The
normal reference ranges were: for iPTH 11-62pg/ml, for insulin
6-20mU/L, and for C-peptide 0.3-0.8 mmol/L.  Estimates of
pancreatic beta-cell function and relative insulin resistance were
calculated from fasting insulin and glucose concentrations using
the Homeostatic Model Assessment score [HOMA BETA (%) =
fasting insulin (mU/L) x 20/fasting serum glucose (mmol/L)-
3.5 and HOMA IR (mU/L) = fasting insulin (mU/L) x serum
glucose (mmol/L)/22.5].15  Anthropometric measurements were
done by one observer.  The percentage of body fat mass was
estimated from skinfold measurement and was compared to
standard anthropometric tables.18
Statistical analysis
Data are presented as mean±SD.  Differences between
groups were evaluated by unpaired two-tailed Student’s t tests
and one-way ANOVA with Bonferroni or Tukey multiple
comparison post-test.  Linear regression models were used to
explore the relationship between HOMA BETA or HOMA IR
and other variables.  All statistical analyses were done using
statistical package SPSS for Windows 8.0.
Results
The clinical characteristics of the participating subjects are
reported in Table 1.  There were no differences for age, sex, and
HD duration between the groups.  When we compared clinical
profiles, besides significantly higher serum iPTH in Gp.2 than
in Gp.1, insulin resistance (HOMA IR) was significantly, but
only slightly, higher (p=0.054) in Gp.2 than in Gp.1.  In contrast
the values for HOMA  IR were significantly higher in both groups
of HD patients as compared to controls.  Insulin secretion
(HOMA BETA) was higher in HD patients, but significantly so
only in Gp.1.  The high SD may have been influenced by the
small number of patients in that group.  The mean values of
glucose (5.0±1.0mmol/l in Gp.1, 5.2±0.8mmol/l in Gp.2) in the
HD patients were significantly higher than the value of the
control group (4.6±0.4mmol/l in Gp.3).  There were no
differences for fasting serum Ca2+, iP and Ca x iP product, BUN,
creatinine and the indexes of body fat, nutritional status and
protein intake (skin folds, BMI, serum protein, albumin and
nPCR) between the groups.  There was a significant negative
correlation between HOMA  IR and HD duration, and HOMA
IR and the creatinine level.  However there was no correlation
of IR with other parameters in Gp.1. HOMA  IR correlated
directly with serum iPTH only in Gp.2 (r=0.544, p=0.03)
Table 1: Clinical and biochemical characteristics of  relative hypoparathyroid  (Gp.1) and hyperparathyroid (Gp. 2)
HD patients and controls (Gp. 3)
Gp. 1 Gp.2 P 
1/2
Gp. 3 P 
1/3, 2/3
N 9 18 43
Mean Age 
(year)
53.6±8.3 49.5±7.0 ns 48.2±6.5 ns, ns
Dialysis Duration
(month)
67.1±14.7 78.9±38.2 ns
Albumin
(mmol/l)
38.0±5.0 38.3±3.6 ns 41.1±2.1 0.01,0.00
Creatinine
(mmol/l)
635.5±179.8 625.5±187.6 ns 94.5±6.4 0.00,0.00
Glucose
(mmol/l)
5.0±0.9 5.2±0.7 ns 4.5±0.4 0.04,0.02
Insulin 
(mU/l)
15.2±5.5 20.1±7.8 ns 9.8±4.4 0.05,0.00
C-peptide
(nmol/l)
2.18±1.0 2.25±0.9 ns 0.91±0.3 0.00,0.00
HOMA IR 3.28±1.3 4.80±2.4 0.05 1.70±0.8 0.03,0.00
HOMA BETA 391.6±667.7 266.9±121.4 ns 167.5±139.7 0.02,ns
Ca2+ 
(mmol/l)
1.10±0.9 1.17±0.1 ns
iP 
(mmol/l)
1.80±0.3 1.89±0.4 ns
Ca2+ x iP 1.98±0.3 2.19±0.5 ns
iPTH 
(pg/ml
) 102.8±31.2 876.0±447.5 0.00
BMI 
(kg/m2)
23.3±2.1 22.6±3.1 ns 23.5±2.3 ns,ns
WHR 0.87±0.1 0.90±0.1 ns 0.89±0.1 ns,ns
Body fat mass 
(%)
24.88±7.0 25.9±7.4 ns 27.6±5.2 ns,ns
NPCR
(g/Kg/d)
1.19±0.2 1.27±0.3 ns
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(Table 2).  Some extent of correlation between HOMA IR and
iPTH existed in Gp.1 but this was not significant.  Within Gp.3,
HOMA  IR correlated directly with BMI (r=0.45, p=0.002) and
WHR (r=0.63, p=0.00).  HOMA BETA inversely correlated with
Ca x iP product in Gp.1 (r= -0.689, p=0.04) (Table 3).  There
was a significant negative correlation between HOMA BETA and
age (r=0.594, p=0.01) but there was no significant correlation
with serum Ca2+ in Gp.2 (Table 3).  Serum iPTH correlated
positively with serum Ca2+ (r= 0.489, p= 0.03) in Gp.2.
Discussion
A number of studies in subjects with end-stage renal failure
(ESRF) have confirmed hyperinsulinemia with reduced insulin
sensitivity and hyperglycaemia.2,3  The accepted gold standard
of insulin sensitivity, the euglycemic hyperinsulinemic clamp,
confirmed reduced insulin sensitivity in end-stage renal failure2.
In this study, the Homeostatic Model Assessment Method for
the calculation of insulin resistance and beta cell function, which
is generally accepted for epidemiological studies, was used.
Since pure insulin level in ESRF represents the result of both
secretion and elimination, reduced elimination by dialyzers,
reduced hepatic insulin clearance as in other subjects with
insulin resistance, and oversecretion of insulin, with decreased
sensitivity to insulin in peripheral tissues, may contribute to
hyperinsulinemia.  The measurement of C-peptide, with values
which correlated excellently with serum insulin and/or the
homostatic model of beta cell function, HOMA BETA, has been
reported earlier.
We have found reduced insulin sensitivity in both groups of
patients but the difference between them was only of borderline
significance.  In the patients with relative hypoparathyroidism,
the index of insulin resistance correlated inversely only with
HD duration and directly with creatinine level.  In the group
with secondary hyperparathyroidism, the degree of insulin
resistance was even more marked and a relationship between
insulin resistance index and serum iPTH level is reported here.
The present findings of reduced insulin sensitivity in the patients
with secondary hyperparathyroidism further confirm similar
reports by other investigators1,2,17.  Elevated PTH correlated with
high serum ionized calcium concentration suggesting that any
resultant insulin resistance concentrations have been already
established.1-3,17  Obesity, differences in body mass index, waist/
hip ratio, or in protein and albumin levels were excluded in both
groups of HD patients.  There was no correlation between body
composition and insulin levels, in our patients, as we found in
controls, in agreement with the findings reported in another
study.18  Therapeutic and environmental factors, such as dietary
calcium, vitamin D, calcitriol use and physical activity were
similar in both groups of the ESRF patients.   Some studies have
shown diminished expression of vitamin D receptors,
particularly in hyperplastic parathyroid glands, as a
consequence of disturbed genomic effects of active vitamin D
induced by the action of a low molecular weight substance in
uremia 9.  The study of Kauzcky-Willer reported an effect of
biologically active vitamin D on the insulin sensitivity of
peripheral tissues which was independent of PTH secretion.12
The lack of significant correlation between insulin sensitivity
and serum PTH in the group with relative hypoparathyroidism
may be a consequence of the small number of participants, better
mineral and hormone homeostasis, or some other mechanism
that might independently affect insulin sensitivity in relatively
hypoparathyroid ESRF patients. 10  That group of patients had
lower levels of serum iPTH and Ca 2+.  Better expression of
vitamin D receptors in these patients might contribute to
reduced insulin sensitivity in peripheral tissue.  One could
speculate that expression of vitamin D receptor and Ca-sensing
receptor may regulate PTH level and insulin sensitivity and /or
insulin secretion at the same time, independently.  The presence
of oxidative stress, as a consequence of the higher plasma
glucose present in both HD groups and higher non-esterified
free fatty acids (NEFA), could be a potential modulator of the
mechanisms involved in insulin resistance in both groups of
HD patients.  Correlation of vitamin D depletion in secondary
hyperparathyroidism has been followed by reductions in NEFA
concentrations and insulin resistance.13
Beta cell function differed from control subjects, in both
Table 2: Multiple correlation (Pearson’s correlation
coefficient r) for HOMA IR of  relative hypoparathyroid
(Gp. 1) and hyperparathyroid (Gp. 2) HD patients
Gp.1 p Gp. 2 p
HOMA IR HOMA IR
         r        r
HD duration -0.67 0.04 -0.07 0.78
Creatinine -0.65 0.05 0.12 0.65
iPTH 0.46 0.21 0.54 0.03
Table 3: Multiple correlation (Pearson’s correlation
coefficient r) for HOMA BETA of  relative hypoparathyroid
(Gp. 1) and hyperparathyroid (Gp. 2) HD patients
Gp.1 p Gp. 2 p
HOMA BETA HOMA BETA
  r        r
Age 0.27 0.48 -0.59 0.01
Ca2+ -0.09 0.81 -0.34 0.19
Ca2+x iP -0.69 0.04 -0.27 0.91
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groups of HD patients, with over-secretion of insulin.  The
HOMA BETA index was significantly higher only in relatively
hypoparathyroid patients.  The etiology of beta cell dysfunction
in ESRF is not clear but it is believed that overactivation of the
CaR inhibits basal and nutrient-stimulated insulin secretion.6,7
In this study, in the relatively hypoparathyroid group, the
HOMA BETA index correlated negatively only with the Ca2+ x
iP product, but in the hyperparathyroid group, HOMA BETA
index showed no significant correlation with serum Ca2+.  The
higher level of serum glucose documented in both groups of
patients, could be also implicated as a potential modulator of
insulin secretion.  Early correction of vitamin D depletion has
been shown to restore both insulin secretion and normoglycemia
in dialysis patients developing glucose intolerance with failing
l-hydroxylation of 25-hydroxy-vitamin D.19  It could therefore
be hypothesised that a low level of active vitamin D and/or high
extracellular Ca2+, or a high Ca2+ x iP product may result in beta
cell dysfunction in those patients.  Extracellular Ca2+ influx
through VDCC raises free cytoplasmic Ca2+ levels and triggers
insulin secretion.  There was a negative correlation between beta
cell secretion and the Ca2+ x iP product documented in relative
hypoparathyroid HD patients.  The preserved beta cells function
in both groups of our patients, suggests relatively good
sensitivity of CaR in beta cells to extracellular calcium.  In
hyperparathyroid patients one may expect abnormal calcium
sensing.
In conclusion, the present study has demonstrated the
presence of a higher level of serum insulin and insulin resistance
in HD patients, as assessed by the calculation of HOMA IR score.
Patient with severe hyperparathyroidism have a higher level of
insulin resistance and there is an association between insulin
resistance and iPTH levels.  Serum iPTH correlated directly with
serum Ca2+ only in hyperprathyroid patients.  Beta cells function
was overexpressed in both groups but reached statistical
significance only in relatively hypoparathyroid patients. It
depended on Ca2+ x iP product in relatively hypoparathyroid
patients only.  Further studies are required using larger numbers
of patients to determine whether parathyroidectomy might
restore insulin sensitivity and partly beta cell function in
hyperparathyroid patients and for definite conclusions to be
made in the hypoparathyroid group of HD patients.
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